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Abstract
Background: Chronic obstructive pulmonary disease is a progressive lung disease that is punctuated by periods of
exacerbations (worsening of symptoms) that are attributable to viral infections. While rhinoviruses are most commonly
isolated viruses during episodes of exacerbation, influenza viruses have the potential to become even more problematic
with the increased likelihood of an epidemic.
Methodology and Principal Findings: This study examined the impact of current and potential pharmacological targets
namely the systemic corticosteroid dexamethasone and the peroxisome proliferator-activated receptor- gamma agonist
pioglitazone on the outcome of infection in smoke-exposed mice. C57BL/6 mice were exposed to room air or cigarette smoke
for 4 days and subsequently inoculatedwith an H1N1 influenza A virus.Interventions were delivered daily duringthe courseof
infection. We show that smoke-exposed mice have an exacerbated inflammatory response following infection. While smoke
exposure did not compromise viral clearance, precision cut lung slices from smoke-exposed mice showed greater expression
of CC (MCP-1, -3), and CXC (KC, MIP-2, GCP-2) chemokines compared to controls when stimulated with a viral mimic or
influenza A virus. While dexamethasone treatment partially attenuated the inflammatory response in the broncho-alveolar
lavage of smoke-exposed, virally-infected animals, viral-induced neutrophilia was steroid insensitive. In contrast to controls,
dexamethasone-treated smoke-exposed influenza-infected mice had a worsened health status. Pioglitazone treatment of
virally-infected smoke-exposed mice proved more efficacious than the steroid intervention. Further mechanistic evaluation
revealed that a deficiency in CCR2 did not improve the inflammatory outcome in smoke-exposed, virally-infected animals.
Conclusions and Significance: This animal model of cigarette smoke and H1N1 influenza infection demonstrates thatsmoke-
exposed animals are differentially primed to respond to viral insult. While providing a platform to test pharmacological
interventions, this model demonstrates that treating viral exacerbations with alternative anti-inflammatory drugs, such as
PPAR-gamma agonists should be further explored since they showed greater efficacy than systemic corticosteroids.
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Introduction
Viral infections have been implicated as a major cause of
chronic obstructive pulmonary disease (COPD) exacerbations.
These episodes lead to declined lung function and concomitant
acute deteriorations in respiratory health [1]. Hospitalization rates
have been shown to increase during the influenza season,
particularly in unimmunized COPD populations [2]. These
episodes place an exorbitant burden on health care systems and
lead to similarly high patient mortality.
While cigarette smoking is the primary etiological factor for
COPD itself [3], exacerbations are caused predominantly by viral
and bacterial infections [4], with as many as 40 to 60% of all
exacerbations attributed to respiratory viral infections alone
[5,6,7]. While rhinoviruses and respiratory syncytial virus are
responsible for the largest fraction of those exacerbations, seasonal
influenza has also been shown to be a significant cause of acute
episodes. Unfortunately, while the relative contribution of
influenza virus to COPD exacerbations is thought to be less
serious in regions that offer immunization [8], and immunization
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patients believe it may trigger exacerbations and thus refuse
vaccination [9,10], making it a persistent threat.
Few studies have examined the effects of cigarette smoking on
antiviral responses in vivo. We have previously shown that a high
dose influenza infection following smoke-exposure causes increased
inflammation without impairing influenza-specific immunologic
memory [11], providing further support for the efficacy of
vaccination. More recently, Gualano and colleagues showed the
inflammatory response that ensues following smoke-exposure does
not protect against influenza virus infection, but rather worsens the
host response [12]. In a study by Kang et al. cigarette smoke was
shown to selectively augment the airway- and alveolar- inflamma-
tory and remodeling responses elicited by viral pathogen- associated
molecular patterns and influenza A virus [13]. These studies suggest
that cigarette smoke-induced inflammation plays a defining role in
the initial inflammatory responses to influenza infection.
The objective of this study was to examine how therapeutics
could target inflammatory responses in smoke-exposed virally-
infected mice. We hypothesized that targeting the excessive
inflammation observed in these animals would lead to a better
clinical outcome. To test our hypothesis, we exposed mice to
cigarette smoke for four days, which we have previously shown
causes a mild inflammation [14], and subsequently infected them
with a mouse-adapted H1N1 influenza A virus. Dexamethasone, a
corticosteroid, and pioglitazone, a peroxisome proliferator-acti-
vated receptor (PPAR)-gamma agonist, were delivered daily. We
show that pioglitazone had greater efficacy in smoke-exposed
influenza-infected mice when compared to the systemic steroid
intervention. Collectively, these data demonstrate that while the
PPAR-gamma agonist, pioglitazone, significantly attenuates in-
flammatory responses and was superior to the effects systemic
corticosteroids elicited in this model; alternative anti-inflammatory
therapies may thus lead to new interventions for the treatment of
viral exacerbations of COPD. Some of the results of these studies
have been previously reported in the form of abstracts [15,16,17].
Results
Cigarette smoke exacerbates the inflammatory response
to influenza A virus infection
Viral infections are well understood to exacerbate inflammation
in smokers [18]. While we and others have shown that cigarette
smoke exacerbates the inflammatory response to influenza virus
infection [11,12,13], the whole body smoke-exposure system used
in this study has not, to our knowledge, been shown to exacerbate
the inflammatory response to influenza infection in mice. Thus, to
assess if inflammation was altered in virally-infected smoke-
exposed animals, mice were exposed to cigarette smoke and
subsequently inoculated with a mouse-adapted H1N1 influenza A
virus. Room air-exposed controls and smoke-exposed animals
showed no differences in the total number of inflammatory cells
recovered in the broncho-alveolar lavage (BAL) at both one and
three days after infection with influenza virus (Figure 1A, upper
panel). We observed an exaggerated inflammatory response in
smoke-exposed influenza-infected animals compared to controls at
five days post-infection, comprised of increased numbers of both
mononuclear and neutrophilic cells. Representative light photo-
micrographs of formalin fixed lung tissues from all groups showed
this exaggerated inflammation at five days post-infection in smoke-
exposed influenza-infected mice (Figure 1B). We also observed
greater inflammation in smoke-exposed influenza-infected animals
seven days post-infection (Figure 1A). As previously reported, this
model of smoke-exposure causes significant neutrophilic inflam-
mation, which subsides following smoking cessation ([14], and
Figure 1A, inset graph).
Clearance of influenza and type I interferon responses
are not impaired in smoke-exposed animals
To determine if the exacerbated inflammation observed in
smoke-exposed animals was the result of greater virus replication,
we assessed viral titres in the lung. We observed no difference in
the amount of virus recovered from room air and smoke-exposed
animals (Figure 2A). Along similar lines, when we assessed type I
interferon activity (IFN is an antiviral cytokine detrimental to the
control of viral infection), we observed greater IFN activity in the
BAL of influenza-infected smoke-exposed animals than in that of
influenza-infected control mice (Figure 2B). Taken together, these
data suggest that cigarette smoke exacerbates the inflammatory
response to influenza A virus without impairing antiviral immune
responses.
Precision cut lung slices elaborate increased levels of pro-
inflammatory chemokines
Since an increased viral burden in smoke-exposed animals did not
appear to be contributing to the exaggerated inflammation observed
in those animals, it is plausible to argue that a smoke-exposed lung is
responding differently to a viral stimulus, which may be contributing
tothe exaggeratedresponse.Toassessthe immunologicalstateof the
lung at the time of viral infection we generated precision cut lung
slices (PCLS), as this unique and informative tool would allow us to
examine the impact of a viral stimulus on the lung resident cells
without further considering the impact of cells that have been
recruited to the lung from the periphery. PCLS (Figure 3A) from the
lungs of room air- and smoke- exposed animals were stimulated ex
vivo with the dsRNA ligand, polyinosinic polycytidylic acid (polyI:C)
and influenza A virus, and expression of key mediators was assessed
by real-time quantitative RT-PCR. Basal expression levels of
monocyte chemotactic proteins (MCP)-1 and MCP-3 (Figure 3B),
and granulocyte chemotactic protein (GCP)-2, KC, and macro-
phage inflammatory protein (MIP)-2 (Figure 3C) were significantly
greater in mock treated smoke-exposed lung slices. We observed a
significantly greater induction of MCP-1 and MCP-3, GCP-2, KC,
and MIP-2 inresponsetopolyI:Cstimulation of smoke-exposed lung
slices compared to controls (Figure 3B and 3C, respectively). Smoke-
exposed lung slices infected ex vivo with influenza virus also had
significantly greater induction of MCP-1, MCP-3, GCP-2, KC, and
MIP-2 compared to influenza infected room air controls. In contrast
to our in vivo type I IFN data (refer to Figure 2B), we observed no
significant differences in the levels of induction of interferon
stimulated gene (ISG)-15 or interferon regulatory factor (IRF)-7
from smoke-exposed PCLS compared to controls when stimulated
with polyI:C (Figure 3D). These data demonstrate that a smoke-
exposed lung is differentially primed when compared to controls to
respond to a viral insult, since increased expression of inflammatory
mediators is observed, despite equivocal levels of antiviral type I
interferons. Importantly, these findings provided the rationale to
assess if targeting the inflammatory response, as opposed to the viral
burden, would improve the inflammatory outcome of infection in
smoke-exposed animals.
Administration of corticosteroids does not beneficially
impact the outcome of influenza infection in smoke-
exposed animals
Since systemic corticosteroids are currently recommended in
the treatment of exacerbations of COPD [19,20] and considering
that we observed dysregulated inflammatory mediator expression
Influenza and Cigarette Smoke
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of dexamethasone would impact the exacerbated inflammation
observed following viral infection of smoke-exposed animals. Mice
were given a previously established dose of oral corticosteroids
[21] one hour prior to viral infection and daily thereafter. In-line
with previously published data [22,23], dexamethasone was not
able to attenuate influenza-induced inflammation five days post-
infection (Figure 4A). Although dexamethasone significantly
attenuated BAL mononuclear inflammation in smoke-exposed
influenza-infected mice, it had no significant impact on overall
inflammation in the BAL (p=0.082) and in fact resulted in
worsened clinical presentation (Figure 4A and B). We did observe
a trend toward increased viral burden in smoke-exposed
dexamethasone-treated animals (Figure 4C), and therefore sought
to determine if dexamethasone treatment had a detrimental
impact later in the course of infection. Although one dexameth-
asone-fed smoke-exposed influenza-infected animal reached end-
point seven days post-infection, these animals did not have
significantly worsened clinical presentation or increased viral titres
(Figure 4D and E, respectively). Thus, systemic corticosteroid
delivery may not be a favorable treatment in the context of an
influenza virus infection of smoke-exposed mice.
The PPAR-gamma agonist pioglitazone ameliorates the
outcome of infection in smoke-exposed animals
Since corticosteroids were shown to be only partially effective in
controlling the exacerbated inflammatory response to influenza
infection in smoke-exposed mice and considering that the clinical
outcome in mice was not entirely favorable, we sought to assess
whether an alternative anti-inflammatory strategy shown to be
effective during influenza infection would treat the increased
inflammation observed in smoke-exposed animals. Recently,
Aldridge et al. published that the type II diabetes drug, pioglitazone,
a PPAR-gamma agonist, was effective in attenuating inflammatory
responses in mice infected with influenza [24]. Pioglitazone along
with another PPAR-gamma agonist, rosiglitazone, have also had a
beneficial effect in animal models of neutrophilic inflammation
[25,26]. We demonstrated with a previously established dose [24]
that pioglitazone-fed room air control animals had significantly
attenuated (p=0.021) total numbers of inflammatory cells in the
BAL following infection compared to vehicle-fed mice (Figure 5A).
While numbers of mononuclear cells were significantly reduced
(p=0.011), neutrophils recovered from the BAL were only modestly
attenuated (p=0.052) in those animals. Given that pioglitazone
ameliorates the inflammatory outcome following infection with this
Figure 1. Influenza infection of smoke-exposed animals. C57BL/6 mice were exposed to room air (open bars) or cigarette smoke (closed bars).
Subsequently, mice were given a PBS vehicle or inoculated with influenza A virus intranasally. (A) Broncho-alveolar lavage (BAL) samples were
obtained and total cells were enumerated at the indicated times post-infection. Mononuclear cell and neutrophil differentials were also assessed. (B)
Light photomicrographs of representative hematoxylin and eosin –stained cross sections of lung tissue were taken at 5 days post-infection. Data are
presented as means 6 SEMs for n=3–12 animals per group.
doi:10.1371/journal.pone.0013251.g001
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our smoke-exposed influenza-infected animals and found that the
exaggerated inflammation observed in smoke-exposed virally
infected animals could be significantly attenuated. In contrast to
influenza-infectedcontrolanimals,smoke-exposedmicedidnothave
significantly attenuated mononuclear (p=0.07) or neutrophilic
(p=0.063) inflammation. All influenza infected animals lost body
weight during the course of infection; however, pioglitazone-treated
smoke-exposed mice lost less than did their control-treated
counterparts (Figure 5B). In line with observations made by Aldridge
et al., pioglitazone did not impact viral clearance incontrol mice, and
furthermore did not alter clearance in our smoke-exposed animals
(Figure 5C).
Since pioglitazone treatment altered the excessive inflammation
observed in smoke-exposed virally-infected animals, we wanted to
further characterize what effect pioglitazone was having on
different cell types within the lung. We thus carried out an
extensive flow cytometric analysis of whole lung digests. Pioglita-
zone had been previously reported to attenuate the TNF-a/
inducible nitric oxide synthase (iNOS)-producing dendritic cell
(tipDC) populations [24], thus we also examined whether this
population may play a role in attenuating inflammation in our
smoke-exposed animals. We were unable to detect any differences
in percentages of this population in pioglitazone-treated controls,
or in pioglitazone-treated smoke-exposed animals (Figure 5D). We
did not observe any differences in B cells (data not shown);
however, we did observe significantly greater percentages of both
activated CD4
+ and CD8
+ T cells in smoke-exposed pioglitazone-
treated animals compared to controls (Figure 5E), despite no
changes in the percentages of these cell types (data not shown).
Taken together, these data suggest a role for PPAR-gamma
agonists as anti-inflammatory agents that are able to impact the
excessive inflammation observed in smoke-exposed influenza-
infected animals without impairing viral clearance.
CCR2 deficiency does not have a beneficial effect on
influenza-related inflammation in smoke-exposed hosts
Given that pioglitazone has been shown to attenuate levels of
cytokines that act through the CCR2 receptor, and several studies
have shown that a deficiency in CCR2 signaling ameliorates the
detrimental effects of influenza infection [24,27,28], we assessed
whether blocking CCR2 signaling would lead to a better outcome
in our smoke-exposed mice. Interestingly, complete absence of the
CCR2 receptor did not attenuate the exaggerated inflammation
observed in the BAL of smoke-exposed influenza-infected animals
(Figure 6A). While the level of mononuclear cells was attenuated,
greater numbers of neutrophils were found in the BAL of CCR2
deficient smoke-exposed, influenza-infected animals than in wild-
type controls. In addition, body weight loss and viral titres were
unchanged in smoke-exposed influenza-infected CCR2 deficient
mice compared to controls (Figure 6B and C). In a similar fashion
to our PPAR-gamma agonist experiments, we assessed whether
there were any observable differences in cell types within the lung
of the CCR2-deficient animals by a flow cytometric analysis.
While a CCR2 deficiency led to attenuated percentages of tipDCs
in influenza-infected mice compared to controls (Figure 6D), as
previously reported [24], percentages of CD69
+, CD4 and CD8 T
cells were significantly attenuated in CCR2 deficient mice
(Figure 6E). Thus, while the PPAR-gamma agonist, pioglitazone,
significantly attenuated exaggerated inflammatory responses in
smoke-exposed mice, a CCR2 deficiency did not appear to confer
any beneficial effect on smoke-exposed influenza-infected animals.
Discussion
It is well understood that viral infections trigger COPD
exacerbations [29]. Given the increased likelihood of an influenza
epidemic, and the contribution of influenza viruses to COPD
exacerbations, the objective of this study was to test current and
novel therapeutics for their ability to reduce the exaggerated
inflammation observed in virally-infected smoke-exposed animals.
Ultimately understanding how we may alter anti-influenza
responses in the lung of smoke-exposed mice will hopefully
translate to promising pharmacological intervention strategies that
may be used in the treatment of viral-induced exacerbations of
COPD.
Using a mouse model of whole-body cigarette smoke exposure
to test our hypothesis, we show that animals mount an exaggerated
inflammatory response to a mouse-adapted influenza A virus. We
Figure 2. Viral titres and type I interferon responses. C57BL/6 mice
were exposed to room air (open bars) or cigarette smoke (closed bars).
Mice were infected with influenza A virus. (A) Viral titres were determined
in lung homogenates at the indicated times post-infection. (B) The
presence of type I interferons at day 3 post-infection was also determined
by plating the indicated dilutions of BAL on confluent monolayers of IRF-3
deficient mouse embryonic fibroblasts and performing a vesicular-
stomatitis virus (VSV) plaque reduction assay. 100% relative intensity
indicates the absence of type I interferon activity, whereas 0% relative
intensity indicates sufficient levels of type I interferon to completely
prevent VSV-GFP replication. Data are presented as the means 6 SEMs for
n=3–17 animals (A), and n=5 animals (B) per group.
doi:10.1371/journal.pone.0013251.g002
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this system causes a mild neutrophilic inflammation within the
lung of C57BL/6 mice [14]. In addition, the protocol of smoke
exposure has been previously validated and shown to achieve
blood carboxyhaemoglobin levels that are comparable to those
found in regular human smokers [21]. While it might be argued
that four days of smoke exposure is a minimal exposure protocol,
we also observed exaggerated inflammatory responses to influenza
A virus with eight weeks of smoke exposure (unpublished
observation). Given that COPD is a very complex disease,
modeling the aspects that include, but are not limited to,
emphysema, bronchitis and bronchiolitis, which contribute to
disease pathogenesis in humans, has to our knowledge never been
achieved in concert in mice. Kang et al. recently demonstrated that
early innate immune events were detrimental to the development
of emphysema in smoke-exposed mice [13], providing further
rationale for examining the impact of acute cigarette smoke
exposure to H1N1 influenza antiviral responses.
Few studies in the literature have examined the effects of
cigarette smoke exposure on antiviral responses. Recently,
Gualano and colleagues showed that smoke-exposed BALB/c
mice that were infected with influenza A virus had greater viral
burden at early timepoints (day 3) post-infection [12]. In contrast,
we did not observe increased titres in our smoke-exposed animals.
While their study argued that increased titres may have been the
result of decreased type I interferon responses, we observed greater
type I interferon activity in our smoke-exposed mice. Furthermore,
our precision cut lung slice data also suggested that type I
interferon responses are in-tact in smoke-exposed lungs as we did
not observe any differences in the induction of key interferon
stimulated genes, ISG-15 and IRF-7, in response to stimulation
with dsRNA ligands. Because these studies used different smoke-
exposure systems, strains of mice and viruses, direct comparison of
these data are difficult; however, it should be noted that we have
previously reported greater levels of type I interferons using a nose-
only smoke exposure system with the parental strain of our virus
[11]. In agreement with our data, a study by Kang and colleagues
also reported similar viral titres in smoke-exposed animals
compared to controls at all time-points post-infection [13]. Taken
together, our data suggest that innate type I interferon-mediated
antiviral responses are not impaired in smoke-exposed mice.
Furthermore, it is unlikely that the initial viral burden in smoke-
Figure 3. Expression of mediators from precision cut lung slices. C57BL/6 mice were exposed to room air (open bars) or cigarette smoke
(closed bars). (A) Precision cut lung slices were generated and cultured ex vivo. Induction of MCP-1 and MCP-3 (B) and GCP-2, KC, and MIP-2 (C)
transcripts, normalized to levels of a house keeping gene, GAPDH, in the same sample and expressed relative to an untreated sample, were obtained
from dsRNA (polyI:C) stimulated and influenza infected precision cut lung slices by real-time quantitative RT-PCR. Induction of ISG-15 and IRF-7 were
determined similarly (D). Data are presented as means 6 SEMs for n=5–15 lung slices generated from 3 independent experiments (polyI:C studies)
and a representative experiment (influenza studies).
doi:10.1371/journal.pone.0013251.g003
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at later times post-infection.
Having established in this study that cigarette smoke was
impacting the inflammatory response to influenza A virus, and not
initial replication and clearance of the virus, and since mounting
evidence suggests that COPD exacerbations are inflammatory
events (reviewed in [29,30,31]), we chose to focus the remainder of
this study on addressing whether exaggerated inflammation could
be attenuated. Using PCLS, we were able to ascertain that the
resident cells within the smoke-exposed lung were producing
greater transcript levels of inflammatory chemokines in response to
a dsRNA stimulus and to an influenza virus infection ex vivo. These
data provided further evidence to support the notion that the
smoke-exposed lung is differentially primed to respond to an
inflammatory stimuli, given that basal levels of all transcripts
measured were significantly greater in smoke-exposed compared
to room air control PCLS.
There are a number of treatments that reduce the incidence and
severity of COPD exacerbation, included among these are inhaled
and oral steroids, combinations of inhaled steroids and beta agonists
[32], as well as the anti-muscarinic Tiotropium [33]. Thus, we first
sought to assess if first-line treatments used in the clinic, such as
systemic corticosteroids, could ameliorate inflammatory outcomes
in influenza-infected smoke-exposed mice. Although it is under-
stood that treating the cytokine storm observed during an influenza
infection with steroids is in-effective [22,34], no studies to our
knowledge involving models of cigarette smoke and virus have
addressed if a steroid intervention would control the exacerbated
responses observed in smokers. To this end, we delivered a dose of
corticosteroids, which we had previously shown in a model of
cigarette smoke and non-typeable Haemophilus influenzae infection to
attenuate exaggerated inflammatory responses [21]. While the
steroid intervention failed to attenuate inflammation, we did
observe a significantly worsened clinical presentation in mice early
Figure 4. Effect of dexamethasone in smoke-exposed influenza-infected mice. Female C57BL/6 mice were exposed to room air (open bars)
or cigarette smoke (closed bars). One hour prior to treatment with vehicle or inoculation with influenza A virus, mice were gavaged with 3mg/kg of
dexamethasone (dex). Mice were gavaged daily with 3 mg/kg of dex. (A) BAL samples were obtained at 5 days post-infection and total cells were
enumerated. Mononuclear cell and neutrophil differentials were also assessed. Clinical presentation in animals at the time of sacrifice (B), and viral
titres (C) were also determined. Clinical presentation (D), and viral titres (E) were also assessed in mice sacrificed at day 7 post-infection. Data are
presented as the means 6 SEMs for n=4–6 animals per group.
doi:10.1371/journal.pone.0013251.g004
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13251in the course of influenza infection (day five). Although at day seven
we did not observe a statistically worsened clinical presentation in
our smoke-exposed influenza-infected mice, one mouse of five did
reach endpoint. Along similar lines, the viral titres observed at both
days five and seven post-infection did not reach statistical
significance; in contrast, in our model of cigarette smoke exposure
and Haemophilus influenzae infection, systemic corticosteroid treat-
ment significantly impaired bacterial clearance from the lungs of
infected mice. Given that current corticosteroid therapies are well
understood to reduce the frequency of COPD exacerbation [32], it
is plausible that in light of our contrasting data in a viral versus
bacterial model that systemic corticosteroids are preferentially
effectivein decreasingthe inflammationassociated with a given type
of exacerbating insult, a hypothesis that would require further
investigation.
Since we showed that steroid interventions did not play a role in
attenuating the inflammation observed in this model of cigarette
smoke exposure and influenza infection, we examined whether
another anti-inflammatory agent would attenuate the observed
dysregulation in the inflammatory response. PPAR-activators are
putative drug targets in COPD [35,36,37], yet no models of cigarette
s m o k ee x p o s u r ea n dv i r a lo rb a c t e r i a li n f e c t i o nh a v ee x a m i n e dt h e i r
potential. In addition, PPAR-gamma agonists have been shown to
exert beneficial effects in models of acute respiratory distress
syndrome [38], lipopolysaccharide-induced lung neutrophilia [25],
and lethal influenza A virus challenge [24]. Given the compelling
evidence that these agonists could provide important relief of
inflammation during times of viral exacerbations, we chose to
administer a dose of the PPAR-gamma agonist, pioglitazone, to our
mice that had been previously shown to ameliorate the outcome of a
Figure 5. Effect of a PPAR-c agonist, pioglitazone, on antiviral responses in smoke-exposed mice. C57BL/6 mice were exposed to room
air (open bars) or cigarette smoke (closed bars). Starting on the second day of smoke exposure, mice were gavaged daily with 60 mg/kg of
pioglitazone (Pio). Following four days of smoke-exposure, mice were given a sterile vehicle or inoculated with influenza A virus intranasally. (A)
Broncho-alveolar lavage (BAL) samples were obtained at 5 days post-infection and total cells were enumerated. Mononuclear cell and neutrophil
differentials were also assessed. (B) Body weight was monitored throughout the course of the viral infection and expressed relative to body weight on
the day 0 of infection. (C) Viral titres were also determined. Percentages of TNFa/iNOS producing dendritic cells (D), and activated CD4+ and CD8+ T
cells (E) were obtained from the live gate of CD45+ cells. Data are presented as the means 6 SEMs for n=5–6 animals per group.
doi:10.1371/journal.pone.0013251.g005
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agonist is able to significantly attenuate exaggerated inflammatory
responses in the BAL of smoke-exposed influenza-infected mice.
Despite the fact that pioglitazone significantly attenuated the total
number of cells lavaged in the BAL, only a moderate attenuation of
the mononuclear cells (p=0.073) and neutrophils (p=0.063) was
observed. Whileit remains arguablethat the method of deliveryand/
or dosing of the drug may have contributed to the efficacy of the
response, these possibilities are being further explored, as the
beneficial effects of PPAR-gamma agonists have been ascertained
in other studies that utilized intravenous delivery of lower drug doses
(0.3 mg/kg) [38], and oral delivery of different formulations
(rosiglitazone) [25].
While Aldridge and colleagues argue that PPAR-gamma
agonists exert their effects during an influenza infection by
down-regulating the recruitment of TNF-a/i-NOS producing
dendritic cells from the bone marrow [24], we did not observe any
changes in this cell population. This discrepancy may be explained
by the fact that we did not inoculate our mice with a lethal dose of
influenza. Interestingly, following an extensive flow cytometric
analysis of lung digests, the only significant differences observed
were on the percentage of activated (CD69
+) CD4 and CD8 T
cells. As previously reported in influenza-infected room air and
smoke-exposed mice [11], and amongst influenza-infected piogli-
tazone-treated animals (data not shown), percentages of both
subsets of T cells remained unchanged. The increased percentage
of activated T cells, to our knowledge, has never been reported
following pioglitazone administration in smoke-exposed influenza-
infected animals. While pioglitazone was able to ameliorate the
weight loss observed in influenza-infected animals this observation
Figure 6. Effect of a CCR2 deficiency on antiviral responses in smoke-exposed mice. C57BL/6 wild-type (WT) or CCR2 knock-out (KO) mice
were exposed to room air (open bars) or cigarette smoke (closed bars). Subsequently, mice were given a sterile vehicle or inoculated with influenza A
virus intranasally. (A) Broncho-alveolar lavage (BAL) samples were obtained at 5 days post-infection and total cells were enumerated. Mononuclear
cell and neutrophil differentials were also assessed. Percent body weight change throughout the viral infection was documented (B), and viral titres
were also determined (C). Percentages of TNFa/iNOS producing dendritic cells (D), and activated CD4+ and CD8+ T cells (E) were obtained from the
live gate of CD45+ cells. Data are presented as the means 6 SEMs for n=5 animals per group.
doi:10.1371/journal.pone.0013251.g006
Influenza and Cigarette Smoke
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cause weight gain [39]. When considering anti-inflammatory
therapies it is imperative to ensure that host defense mechanisms
are not impaired; in that regard, pioglitazone did not alter
clearance of the virus from our smoke-exposed animals. The fact
that effector CD4 and CD8 T cells are required for the clearance
of RNA virus infections, the increased percentages of activated
CD4 and CD8 T cells likely plays a imperative role in clearing
influenza viruses from the lung despite altering the inflammatory
cells recruited to the lung.
Since pioglitazone is known to exert some of its effects through
the CCR2 receptor, we next sought to examine if a deficiency in
this receptor would attenuate exaggerated inflammation in our
smoke-exposed virally-infected animals. We showed that smoke-
exposed CCR2-deficient mice did not have attenuated inflamma-
tion in response to influenza infection. To assess if there were any
observable differences between our influenza-infected smoke-
exposed pioglitazone-treated and CCR2-deficient animals that
could account for the differences observed in total BAL
inflammation, we carried out a comprehensive flow cytometric
analysis of whole lungs, and found more activated CD4 and CD8
T cells within the lungs of our smoke-exposed and influenza-
infected animals treated with pioglitazone. While CD8
+ T cells
have been shown to be critical for clearance of respiratory viruses,
depending on the number of CD8
+ T cells and overall immune
status, these cells may cause severe lung pathology. While CD8
+ T
cells have been implicated in mice and in humans to contribute to
tissue damage, further studies would be required to assess if this
increase in activated T cells has any implications to changes in a
smoke-exposed lung.
Taken together, the results of our study demonstrate a striking
difference between the inflammatory responses mounted by
smoke- and room air-exposed mice to viral challenge. Data
obtained from PCLS further highlights the notion of a skewed
inflammatory profile in the lung of smokers. In addition, this study
brings to light the potential for PPAR-gamma agonists as anti-
inflammatory agents for the treatment of inflammation associated
with exacerbations of COPD, and demonstrates the value of
mouse models of cigarette smoke exposure and viral infection for
pre-clinical screening of potential therapeutics for patients with
stable COPD and for those suffering from exacerbations of their
disease.
Materials and Methods
Animals
6–8 week old female C57BL/6 mice were purchased from
Charles River Laboratories (Montreal, PQ, Canada) and kept on a
12-h light-dark cycle with unlimited access to food and water.
Cages, food, and bedding were autoclaved. All studies were
approved by the McMaster University Animal Research Ethics
Board. Body weight and clinical presentation of animals were
monitored daily in each study, as previously described [40].
Cigarette Smoke Exposure
Mice were exposed to mainstream tobacco smoke using a whole
body smoke exposure system (SIU48, PROMECH LAB AB,
Vintrie, Sweden), as previously reported [21]. Briefly, mice were
exposed to 12 2R4F reference cigarettes with filters removed
(Tobacco and Health Research Institute, University of Kentucky,
Lexington, KY, USA) twice daily, 5 days per week, for
approximately 50 minutes. An acclimatization period of three
days prepared mice for smoke exposure and has been previously
described [41]. Mice were exposed to 4 days of cigarette smoke
and were no longer exposed following influenza infection. Control
animals were exposed to room air only.
Influenza Infection
Isoflurane-anesthetized mice were intranasally infected with
50 PFU of a mouse-adapted H1N1 influenza A (A/FM/1/47-
MA) virus in 35 ml of phosphate-buffered saline (PBS) vehicle.
Control animals received 35 ml of PBS vehicle. A/FM/1/47-MA
is a fully sequenced, plaque-purified preparation that is biologically
characterized with respect to mouse lung infections [42]. Animals
were not exposed to cigarette smoke on the day of viral delivery or
for the entire course of the viral infection.
Pioglitazone and Dexamethasone Treatment
Mice were treated with a previously established dose [24] of
60 mg/kg pioglitazone (Toronto Research Chemicals, Toronto,
Canada), suspended in 100 mL of PBS, via oral gavage beginning
on day 2 of smoke-exposure and daily thereafter. 3 mg/kg of
dexamethasone, a dose previously established in smoke-exposed
animals [21] was suspended in 200 mL of PBS and delivered via
oral gavage to mice one hour prior to viral inoculation and daily
thereafter. Control mice were gavaged with 100 mL or 200 mLo f
phosphate buffered saline (PBS), respectively, for the pioglitazone
and dexamethasone studies.
Collection and Measurement of Specimens
Lungs were removed, tracheas cannulated (Becton Dickinson
and Co., Sparks, MD, USA), and a lobe from the right lung was
removed for determination of viral titre. Broncho-alveolar lavage
(BAL) was generated by lavaging the lung twice with PBS (250 ml
followed by 200 ml). Total cell counts from the BAL were
determined by haemocytometer. BAL cells were pelleted by
centrifugation and differential cell counts were obtained from
cytospins that were generated after re-suspension of cell pellets.
Cytospin cells were stained by Hema 3 (Biochemical Sciences
INC., Swedesboro, NJ, USA). Differential counts were determined
by counting at least 300 cells. Standard hemocytological criteria
were used to classify mononuclear cells and neutrophils. The
remainder of the right lung was used for flow cytometric analysis,
and the left lung lobe was inflated with formalin for histological
assessment.
Measurement of Viral Titre. Lung homogenates were used
to determine viral titre on Madin-Darby Canine Kidney (MDCK)
monolayers. MDCK cells were maintained in a-MEM
supplemented with 10% fetal bovine serum, 1% L-glutamine, and
1% penicillin/streptomycin. MDCK cells were seeded into 6 well
dishes. Confluent monolayers of MDCK cells were washed twice
with PBS to remove serum. Serial dilutions of lung homogenate
samples wereprepared and200 ml ofeach wasadded totheMDCK
monolayers. Dishes were rocked and incubated at 37uC for 30
minutes. Agarose overlays (1:1 ratio of 1.3% agarose (Biotechnology
grade;Bioshop CanadaINC., Burlington,Canada), and 26MEM/
F-11 supplemented with 2% L-glutamine and 2% penicillin/
streptomycin, containing 1 mg/ml trypsin-EDTA) were applied and
agarose allowed to solidify before replacing dishes to 37uC. Two
days later, plaque assays were fixed using Carnoy’s Fixative (75%
methanol and 25% glacial acetic acid). Plaques were enumerated
and viral titres were expressed as the number of infectious plaque
forming units per gram of lung tissue.
Histological Assessment
The right lung lobe was inflated with 10% formalin at a
constant pressure of 20 cm of H2O. The inflated lung was fixed for
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into 70% ethanol and prepared for paraffin embedding. 3 mm
cross-sections were cut and stained with hematoxylin and eosin.
Images were captured using a Leica camera and microscope
(Leica Microsystems, Richmond Hill, Canada). OpenLab software
(version 3.0.3, Improvision, Guelph, Canada) was used for photo
acquisition.
Flow Cytometric Analysis
Lungs were cut into ,2 mm pieces, shaken for 1 h at 37uCi n
150 U/ml collagenase III (Gibco, Burlington, Canada) in HBSS,
pressed through nylon mesh, washed twice in HBSS, and counted
on a hemacytometer. 10
6 cells were plated in 96-well, round-
bottom plates. Cells were washed, and re-suspended in 25 mlo f
staining cocktail for 30 min at 4uC. Antibodies used in this study
include anti-CD11c (FITC, HL3, BD Biosciences, San Jose, CA,
USA), anti-CD4 (PE-610, RM4-5, Invitrogen, Burlington, Cana-
da), anti-CD69 (PerCP-Cy5.5, H1.2F3, BD Biosciences San Jose,
CA, USA), anti-CD45R (APC-Alexa Fluor 750, RA3-6B2,
eBiosciences, San Diego, CA, USA), anti-CD3 (Pacific Blue,
eBio500A2, eBiosciences, San Diego, CA, USA), and anti-CD8
(Pacific Orange, 5H10, Invitrogen, Burlington, Canada), as well as
appropriate isotype control antibodies (BD, San Jose, CA, USA
and eBiosciences, San Diego, CA, USA). For analysis of TNF-a/
iNOS producing dendritic cells, 10
6 cells were incubated for 4 K
hours in 50 ng/ml PMA and 500 ng/ml ionomycin. Cells were
subsequently surface stained with anti-Ly6c (AlexaFluor 647, BD
Biosciences, San Jose, CA, USA) and CD11b (PE, BD Biosciences,
San Jose, CA, USA), followed by fixation and permeabilization
with BD cytofix/cytoperm (BD Biosciences, San Jose, CA, USA),
and intracellular staining for iNOS (FITC, BD Biosciences, San
Jose, CA, USA) and TNF-a (PE-Cy7, BD Biosciences, San Jose,
CA, USA). Fluorescence minus one staining cocktails and isotype
control antibodies (BD Biosciences and eBiosciences) were used to
distinguish background staining from positive signals. Flow
cytometric data was acquired using an LSRII flow cytometer
(BD Biosciences, San Jose, CA, USA). Data were analyzed with
FlowJo Software (Tree Star, Ashland, OR, USA).
Lung Slicing and Culture
Lungs were sliced using a modification to a standard protocol
that has previously been described [43]. The protocol was adapted
within our laboratory and others [44]. After sacrifice, the tracheas
were cannulated using an intravenous catheter (20 G Intima,
Becton, Dickinson, Sandy, UT, USA), and the chest walls were
removed. Lungs were inflated with approximately 1.4 ml of
agarose (type VII-A low gelling temperature; Sigma Aldrich, St.
Louis, MO, USA) that was warmed to 37uC and prepared to a
concentration of 2% in Hank’s buffered saline solution (HBSS),
supplemented with N-2-hydroxyethlypiperazine-N’-2-ethanesul-
phonic acid (HEPES) (0.2 M, pH 7.4). Subsequently, 0.2 ml of
air was injected into the lung in order to flush the agarose-HBSS
solution out of the conducting airways. The agarose was allowed to
gel by cooling the lung to 4uC for 15 minutes. The lung lobes were
dissected away and a flat surface was cut on the lobe parallel and
caudal to the main bronchus. The lung lobes were maintained in
an ice-cold 16HBSS solution prior to and during slicing. 120 mm
thick slices were generated using a vibratome (Leica; model VT
1000S, Richmond Hill, Canada) at 4uC. Approximately 40 slices
were isolated from each mouse lung.
Lung slices were subsequently transferred to and cultured in
Dulbecco’s Modified Eagles Medium (DMEM)/F12 (Gibco,
Burlington, Canada) supplemented with 35 mg/ml L-Ascorbic
Acid (Sigma-Aldrich, Oakville, Canada), 5 mg/ml Transferin
(Gibco, Burlington, Canada), 2.85 mg/ml Insulin (Sigma-Aldrich,
Oakville, Canada), and 3.25 ng/ml Selenium (atomic absorption
standard solution; Sigma-Aldrich, Oakville, Canada). The solution
was filter-sterilized using a 0.22 mm pore filter. The DMEM/F12
solution was further supplemented with 250 ng/ml Amphotericin
B (Sigma-Aldrich, Oakville, Canada) and 1% Penicillin/strepto-
mycin. The medium was changed every 1 h for the first 3 h of
culture in order to remove any remaining agarose and cell debris
from the lung slice culture. Lung slices were stimulated the next
day for 6 hours with 100 ug/ml of dsRNA mimetic polyinosinic-
polycytidylic acid (GE Healthcare, Mississauga, Canada) that was
reconstituted in phosphate buffered saline, for 24 hours with
200 PFU/ml of a mouse-adapted H1N1 influenza A (A/FM/1/
47-MA) virus, or were left untreated. Samples were collected in
RNA later (Ambion, Austin, TX, USA) and preserved at -80uC
until extraction of RNA.
RNA extraction and Real-Time Quantitative RT PCR
Lung slices were collected and placed into 200 ml of RNAlater
(Qiagen, Mississauga, ON, Canada), and stored at 280uC until
furtheruse. RNAwasextractedfrom thelung slicesaccordingtothe
animal tissues protocol from the RNEasy Kit (Qiagen, Mississauga,
ON, Canada). Optional on-column DNase digestion was per-
formed. RNA was quantified using the Agilent 2100 Bio-analyzer
(Agilent Technologies, Mississauga, ON, Canada). The quantity
and integrity of isolated RNA was determined using the Agilent
2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Subsequently,
100 ng of total RNA was reverse-transcribed using 100 U of
Superscript II (Invitrogen, Burlington, Canada) in a total volume of
20 mL. Random hexamer primers were used to synthesize cDNA at
42uC for 50 min, followed by 15 min incubations at 70uC. Real-
time quantitative RT-PCR was performed in triplicate, in a total
volume of 25 ml, using a Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, USA). Primers for ISG-15, IRF-7,
MCP-1, MCP-3, GAPDH, along with FAM-labeled probes were
purchased from Applied Biosystems. PCR was performed using the
ABI PRISM 7900HT Sequence Detection System using the
Sequence Detector Software version 2.2 (Applied Biosystems,
Foster City, CA, USA). Data were analyzed using the delta, delta
Ct method. Briefly, gene expression was normalized to the
housekeeping gene (GAPDH) and expressed as fold change over
the control group (room air control, mock).
VSV-GFP plaque reduction assays
Type I interferon bioactivity was assessed in BAL samples by
plaque reduction assay as previously described [11]. Briefly,
interferon regulatory factor 3-deficient mouse embryonic fibro-
blasts were seeded into 24 well dishes. Serial dilutions of BAL fluid
were prepared and incubated with the cells for 18 hours. Cells
were subsequently washed with 37uC PBS and incubated with
vesicular stomatitis virus expressing GFP (VSV-GFP; kindly
provided by Dr. Brian Lichty, McMaster University) for 40
minutes in serum-free media. The viral inoculum was removed
and replaced with DMEM containing 1% methylcellulose. GFP
fluorescence intensity was measured 24 hours later on a Typhoon
Trio imager (GE Healthcare, Mississauga, Canada) and quantified
using the ImageQuant
TM TL software (GE Healthcare, Mis-
sissauga, Canada).
Data analysis
Data are expressed as mean 6 SEM. Statistical analysis was
performed with SPSS statistical software, version 17.0 (Chicago,
IL, USA). We assessed significance (p,0.05) using the SPSS
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performed for two-group comparisons.
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